CA-NETAPP
5.3.2024 14:02:00 CET | Business Wire | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced new capabilities that maximize the potential of generative artificial intelligence (Gen AI) projects and build competitive advantage for users. Customers can now take their AI projects to the next level by combining NetApp’s intelligent data infrastructure with high-performance compute, networking and software from NVIDIA.
Gen AI has captured global attention for its potential to automate tedious tasks, uncover new insights, and drive product innovation. Nearly three out of four companies are already using Gen AI, according to the NetApp 2023 Data Complexity report. To unlock the potential of Gen AI, organizations need secure, high-performance access to data spread across complex hybrid and multicloud environments. NetApp has a long and successful history of expertise in supporting AI with solutions that deliver management simplicity anywhere data lives, provide high performance without requiring new infrastructure silos, and supply trusted, secure data to drive responsible AI.
“NetApp is the intelligent data infrastructure company, with solutions optimized to maximize the potential of our customers’ AI investments,” said Arunkumar Gururajan, Vice President of Data Science & Research at NetApp. “Our unique approach to AI gives customers complete access and control over their data throughout the data pipeline, moving seamlessly between their public cloud and on-premises environments. By tiering object storage for each phase of the AI process, our customers can optimize both performance and costs exactly where they need them. Our unified approach delivers the performance, productivity, and protection customers need to quickly innovate with AI.”
To support companies leveraging Gen AI to improve their operations and strategic decision-making, NetApp released updates to its intelligent data infrastructure capabilities including:
- NetApp AIPod™ is NetApp's AI-optimized converged infrastructure for organizations’ highest priority AI projects, including training and inferencing. NetApp AIPod powered by NVIDIA DGX is now a certified NVIDIA DGX BasePOD solution using NVIDIA DGX H100 systems integrated with NetApp AFF C-Series affordable capacity flash systems to drive a new level of cost/performance while optimizing rack space and sustainability. NetApp AIPod powered by NVIDIA DGX also continues to support NVIDIA DGX A100 systems.
- New FlexPod for AI reference architectures extend the leading converged infrastructure solution from NetApp and Cisco. FlexPod for AI now supports the NVIDIA AI Enterprise software platform. FlexPod for AI can now be extended to leverage RedHat OpenShift and SuSE Rancher. New scaling and benchmarking have been added to support increasingly GPU-intensive applications. Customers can use these new FlexPod solutions as an end-to-end blueprint to efficiently design, deploy, and operate the FlexPod platform for AI use cases.
- NetApp is now validated for NVIDIA OVX systems. NetApp storage combined with NVIDIA OVX computing systems can help streamline enterprise AI deployments, including model fine-tuning and inference workloads. Powered by NVIDIA L40S GPUs, validated NVIDIA OVX solutions are available from leading server vendors and include NVIDIA AI Enterprise software along with NVIDIA Quantum-2 InfiniBand or NVIDIA Spectrum-X Ethernet, and NVIDIA BlueField-3 DPUs. NetApp is one of the first partners to complete this new storage validation for NVIDIA OVX.
To further enhance its AI leadership, NetApp also is announcing revolutionary new cyber-resilience capabilities including one of the first uses of AI/ML embedded in storage to fight ransomware. The new Autonomous Ransomware Protection with AI (ARP/AI) will provide the next generation of machine learning in ONTAP, giving the increased accuracy and performance required to detect and mitigate new, more sophisticated cyber threats.
“AI powers mission-critical use cases in every industry, from healthcare to manufacturing to financial services,” said Tony Paikeday, Senior Director of AI Systems at NVIDIA. “NetApp AIPod certified for NVIDIA DGX BasePOD provides a powerful reference architecture that helps enterprises eliminate design complexity, reduce deployment time frames, and simplify ongoing operations.”
“GenAI has massive potential to help organizations harness their data to uncover business insights and improve operational efficiency,” said Archana Venkatraman, Research Director, Cloud Data Management, IDC. “NetApp has continuously adapted to deliver the services and solutions customers need to effectively manage their data pipelines. These updates further illustrate NetApp’s willingness to evolve and bring innovations to customers that unlock the full potential of AI.”
NetApp delivers a unified approach to infrastructure and data management that eliminates data silos, brings enhanced performance and trusted data protection to customers’ AI turnkey solutions, and helps customers accelerate the time to results for their AI projects.
To learn more about the NetApp offerings to support Gen AI, visit: https://www.netapp.com/artificial-intelligence/
Additional Resources
- Your Data, Your AI, Anywhere: Introducing the NetApp AIPod Now Certified on NVIDIA's DGX H100
- FlexPod: Where Converged Meets Cloud
About NetApp
NetApp is the intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305729049/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom